Oral Antivirals against COVID-19 and Clinical Outcomes in High Risk Populations
针对 COVID-19 的口服抗病毒药物和高危人群的临床结果
基本信息
- 批准号:10574806
- 负责人:
- 金额:$ 15.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-12 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Acute myocardial infarctionAddressAffectAmbulatory Care FacilitiesAntiviral AgentsAuthorization documentationCOVID-19Cardiovascular systemCaringCase StudyCessation of lifeCharacteristicsClinic VisitsClinicalCollaborationsCommunicable DiseasesDataDatabasesDiabetes MellitusDiagnosisDiseaseDisparityEarly treatmentEffectivenessElderlyEmergency SituationEmergency department visitEndocrine systemEventFDA Emergency Use AuthorizationGeographic LocationsGrantHepaticHomelessnessHospitalizationImmunityIncidenceInstitutional Review BoardsInternal MedicineInternationalJournalsKidneyKnowledgeLaboratoriesMedicalMedicineMental disordersMetabolicNatural HistoryNatureNew AgentsNew EnglandOralOutcomePaperPatientsPeer ReviewPersonsPharmaceutical PreparationsPolicy MakerPopulationPovertyProviderPublicationsPublishingRecoveryRenal functionReportingRitonavirRoleSARS-CoV-2 infectionSeveritiesSourceStrokeTherapeutic AgentsTimeUnited States Department of Veterans AffairsUnited States Food and Drug AdministrationUpdateVaccinationVaccineeVaccinesVariantVulnerable Populationsauthoritybooster vaccinebreakthrough infectionclinical investigationclinical practicecomorbiditycomparative effectivenessdata sharing networksdata warehousedemographicseffectiveness evaluationeffectiveness studyepidemiology studyethnic minorityevidence baseexperiencegastrointestinalhealth care service utilizationhigh riskhigh risk populationmolnupiravirmortalitynirmatrelvirnovelpharmacologicphysically handicappedpreventprogression riskpublic health emergencyracial minorityresidencerespiratorysocial vulnerability
项目摘要
COVID-19 has led to over 350 million reported cases and over 5.6 million resulting deaths globally, and nearly
72 million cases and >900,000 deaths in the US. Highly effective vaccines are now available and are the first
line of defense. However, immunity wanes off over time and breakthrough infections in fully vaccinated
persons have been reported, particularly with the newer variants. In December 2021, two novel oral antiviral
agents, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir (MPV), were granted Emergency Use Authorization
(EUA) by the FDA for treatment of early symptomatic patients with mild to moderate COVID-19 at high risk of
progression to severe disease. These authorizations were granted based on limited published data, and critical
questions about their comparative effectiveness, effectiveness in the real-world settings, and effectiveness in
specific high-risk sub-populations remain to be answered. There is an urgent need to understand the real-world
effectiveness of these drugs, especially in the high-risk and vulnerable populations, as well as longer term
clinical outcomes in treated patients. Such knowledge is essential for the patients, providers, payors, and
policymakers, to ensure that they are used only in the appropriate populations and situations based on strong
clinical evidence. To address these critical gaps in knowledge, we propose the following hypotheses:
Hypothesis 1: Treatment with NMV/r or MPV will be associated with a significant reduction in COVID-19
related hospitalization and 30-day all-cause mortality in older persons, those with a high comorbidity burden,
and in socially vulnerable persons.
Hypothesis 2: We hypothesize that NMV/r and MPV treatment will be associated with a significant reduction in
subsequent hospital admissions, emergency department visits, and outpatient clinic visits over a 1-year period
after recovery. Treatment will also be associated with a lower incidence of acute myocardial infarction, stroke,
decline in renal function, and diabetes, compared with propensity-score matched untreated persons.
We will use the Department of Veterans Affairs’ COVID-19 Shared Data Resource (VA ORDCOVID) which
contains extensive demographic, clinical, pharmacologic, laboratory, vital signs and clinical outcomes
information derived from multiple validated sources. We will compare those treated with NMV/r or MPV with
propensity-score matched untreated controls, matched on demographics, clinical variables, severity of
presenting illness, geographic location, time of treatment, vaccination status, time from completion of a full
course of vaccination, and booster dose administration. The PI, Dr. Butt has extensive experience in creating
and analysing large national databases and has published 45 papers on COVID-19 in journals including the
New England Journal of Medicine, Annals of Internal Medicine, JAMA Internal Medicine, Journal of Clinical
Investigation, Nature Medicine, and others. He already has IRB approval to study the epidemiology, natural
history, and clinical outcomes of SARS-CoV-2 infection in the VA population.
COVID-19 已导致全球报告病例超过 3.5 亿,死亡人数超过 560 万人,近
美国有 7200 万例病例和超过 90 万人死亡。高效疫苗现已问世,并且是第一个
防线。然而,免疫力会随着时间的推移而减弱,并且在完全接种疫苗的情况下会出现突破性感染
已有人报告,特别是较新的变种。 2021年12月,两种新型口服抗病毒药物
药物 Nirmatrelvir/ritonavir (NMV/r) 和 Molnupiravir (MPV) 获得紧急使用授权
(EUA) 被 FDA 批准用于治疗具有高风险的轻度至中度 COVID-19 早期症状患者
进展为严重疾病。这些授权是基于有限的已发布数据和关键的
关于它们的比较有效性、现实世界环境中的有效性以及在
具体的高风险亚人群仍有待解答。迫切需要了解现实世界
这些药物的有效性,特别是对高危和弱势人群,以及长期效果
治疗患者的临床结果。这些知识对于患者、提供者、支付者和
政策制定者,以确保它们仅在适当的人群和情况下使用
临床证据。为了解决这些关键的知识差距,我们提出以下假设:
假设 1:NMV/r 或 MPV 治疗将与 COVID-19 的显着减少相关
老年人、合并症负担较高的人的相关住院治疗和 30 天全因死亡率,
以及社会弱势群体。
假设 2:我们假设 NMV/r 和 MPV 治疗将与显着降低
一年内的后续入院、急诊科就诊和门诊就诊
恢复后。治疗还可以降低急性心肌梗死、中风、
与倾向评分匹配的未治疗者相比,肾功能下降和糖尿病。
我们将使用退伍军人事务部的 COVID-19 共享数据资源 (VA ORDCOVID),该资源
包含广泛的人口统计学、临床、药理学、实验室、生命体征和临床结果
来自多个经过验证的来源的信息。我们将比较那些接受 NMV/r 或 MPV 治疗的患者
倾向评分与未治疗的对照相匹配,与人口统计、临床变量、严重程度相匹配
显示疾病、地理位置、治疗时间、疫苗接种状况、完成完整检查的时间
疫苗接种过程和加强剂量管理。 PI,巴特博士在创造方面拥有丰富的经验
并分析大型国家数据库,并在期刊上发表了 45 篇有关 COVID-19 的论文,其中包括
新英格兰医学杂志、内科医学年鉴、JAMA 内科医学、临床杂志
调查、自然医学等。他已经获得IRB批准研究流行病学、自然
VA 人群中 SARS-CoV-2 感染史和临床结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ADEEL A BUTT其他文献
ADEEL A BUTT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ADEEL A BUTT', 18)}}的其他基金
Treatment Disparities/Outcomes of HCV-HIV Co-Infection
HCV-HIV 合并感染的治疗差异/结果
- 批准号:
6806978 - 财政年份:2003
- 资助金额:
$ 15.78万 - 项目类别:
Treatment Disparities/Outcomes of HCV-HIV Co-Infection
HCV-HIV 合并感染的治疗差异/结果
- 批准号:
7103381 - 财政年份:2003
- 资助金额:
$ 15.78万 - 项目类别:
Treatment Disparities/Outcomes of HCV-HIV Co-Infection
HCV-HIV 合并感染的治疗差异/结果
- 批准号:
6922766 - 财政年份:2003
- 资助金额:
$ 15.78万 - 项目类别:
Treatment Disparities/Outcomes of HCV-HIV Co-Infection
HCV-HIV 合并感染的治疗差异/结果
- 批准号:
6694586 - 财政年份:2003
- 资助金额:
$ 15.78万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 15.78万 - 项目类别:
Research Grant














{{item.name}}会员




